Sogroya is administered by subcutaneous injection once weekly. The Food and Drug Administration (FDA) has approved Sogroya ® (somapacitan-beco) for the treatment of pediatric patients aged 2.5 years ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications, ...

MISSISSAUGA, ON, Oct. 15, 2025 /CNW/ - Novo Nordisk has announced that Sogroya ® (somapacitan injection) is now commercially available in Canada. Sogroya ® is indicated for the long-term treatment of ...

Sogroya is administered by subcutaneous injection one time each week. The Food and Drug Administration (FDA) has approved Sogroya® (somapacitan-beco; Novo Nordisk) injection for the replacement of ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in the realm of rare disease. Over the weekend, Novo unveiled data from the ...

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

Therapy has been developed for use among children and adolescents with growth hormone deficiency Therapy has been developed for use among children and adolescents with growth hormone deficiency Novo ...

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children aged 3 to 17 years with paediatric growth hormone deficiency. The once-weekly ...

The MarketWatch News Department was not involved in the creation of this content. Sogroya(R) is the first-and-only once-weekly growth hormone treatment for both children and adults living with growth ...